shelf life is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-13. Numbers and descriptions here follow the published literature rather than marketing material.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C for solid; 2-8 °C for short-term solution use | Avoid repeated freeze-thaw cycles |
| Preferred solvent | Water or aqueous buffer near neutral pH | Nonpolar solvents give poor dissolution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Copper quantified separately by ICP-MS |
| Principal degradation routes | Backbone hydrolysis, histidine oxidation, photolysis | Alkaline pH accelerates hydrolysis |
| Counterion form | Acetate salt is common | Counterion contributes to measured mass |
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll. Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease. Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.
=== Grades of sulfuric acid === Although nearly 100% sulfuric acid solutions can be made, the subsequent loss of SO3 at the boiling point brings the concentration to 98.3% acid. The 98.3% grade, which is more stable in storage, is the usual form of what is described as "concentrated sulfuric acid". Other concentrations are used for different purposes. Some common concentrations are:
On May 14, 1913, New York Governor William Sulzer approved a charter for the foundation with Junior becoming the first president. With its large-scale endowment, a large part of Senior's fortune was insulated from inheritance taxes. The first secretary of the foundation was Jerome Davis Greene, the former secretary of Harvard University, who wrote a "memorandum on principles and policies" for an early meeting of the trustees that established a rough framework for the foundation's work. It was initially located within the family office at Standard Oil's headquarters at 26 Broadway, later (in 1933) shifting to the GE Building (then RCA), along with the newly named family office, Room 5600, at Rockefeller Center; later it moved to the Time-Life Building in the center, before shifting to its current Fifth Avenue address. In 1914, the trustees set up a new Department of Industrial Relations, inviting William Lyon Mackenzie King to head it. He became a close and key advisor to Junior through the Ludlow Massacre, turning around his attitude to unions; however the foundation's involvement in IR was criticized for advancing the family's business interests. The foundation henceforth confined itself to funding responsible organizations involved in this and other controversial fields, which were beyond the control of the foundation itself.
Sources: en.wikipedia.org
== Mediated apoptosis == Once inside the target cell, granzyme B can cleave and activate initiator caspases 8 and 10, and executioner caspases 3 and 7 which trigger apoptosis. Caspase 7 is the most sensitive to granzyme B and caspases 3, 8, and 10 are only cleaved to intermediate fragments and need further cleavage for full activation. Granzyme B can also cleave BID leading to BAX/BAK oligomerisation and cytochrome c release from the mitochondria. Granzyme B can cleave ICAD leading to DNA fragmentation and the laddering pattern associated with apoptosis. Granzyme B has a potential of over 300 substrates and can cleave Mcl-1 in the outer mitochondrial membrane relieving its inhibition of Bim. Bim stimulates BAX/BAK oligomerisation, mitochondrial membrane permeability and apoptosis. Granzyme B can also cleave HAX1 (Hs-1 associated protein X-1) to facilitate mitochondria polarisation. Granzyme B can also generate a cytotoxic level of mitochondrial reactive oxygen species (ROS) to mediate cell death. The caspase independent pathways of cell death are thought to have arisen to overcome viruses that can inhibit caspases and prevent apoptosis.
== Olfactory perception == The properties of a compound relating to human olfactory perception includes its odour quality, threshold and intensity as a function of its concentration. The odour quality of a (odour-active) compound is assessed using odour descriptors in sensory descriptive analyses. It shows the sensory–chemical relationship in volatile compounds. The odour quality of a compound may change with its concentration. The absolute threshold of a compound is the minimum concentration at which it can be detected. In a mixture of volatile compounds, only the proportion of compounds present at concentrations above their threshold contribute to the odour. This property can be represented by the odour threshold (OT), the minimum concentration at which the odour is perceived by 50% of a human panel without determining its quality, or the recognition threshold, the minimum concentration at which the odour is perceived and can be described by 50% of a human panel. The intensity of perception of a compound is positively correlated with its concentration. It is represented by the unique psychometric or concentration-response function of the compound.
As of July 22, 2021, the position of the RSPCA is that Australian Merino sheep have not been ethically bred, as seen in their susceptibility to flystrike. They believe "any painful procedure to change the breech area should only be considered an interim, short-term solution that accompanies a breeding program that focusses on flystrike resistance and is carried out only where necessary to manage at-risk sheep".
Sources: en.wikipedia.org
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.
Copper is quantified by an elemental technique such as inductively coupled plasma mass spectrometry, not by peptide chromatography. The chromatographic result describes the peptide chain, while the elemental result describes the metal. Reporting both is what makes the stoichiometry checkable.
It normally lists the analytical methods used, the measured purity, the appearance, and any residuals or counterions detected. It is a statement about a specific batch rather than a general property of the material. Independent testing is still needed when results must be traceable to a reference standard.
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.